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Abstract Heterotopic ossification (HO) refers to the abnormal formation of bone in soft tissue.
Although some of the underlying processes of HO have been described, there are currently no clin-
ical tests using validated biomarkers for predicting HO formation. As such, the diagnosis is made
radiographically after HO has formed. To identify potential and novel biomarkers for HO, we used
isobaric tags for relative and absolute quantitation (iTRAQ) and high-throughput antibody arrays
to produce a semi-quantitative proteomics survey of serum and tissue from subjects with (HO+) and
without (HO) heterotopic ossification. The resulting data were then analyzed using a systems biol-
ogy approach. We found that serum samples from subjects experiencing traumatic injuries with
resulting HO have a different proteomic expression profile compared to those from the matched
controls. Subsequent quantitative ELISA identified five blood serum proteins that were differen-
tially regulated between the HO+ and HO groups. Compared to HO samples, the amount of
insulin-like growth factor I (IGF1) was up-regulated in HO+ samples, whereas a lower amount
of osteopontin (OPN), myeloperoxidase (MPO), runt-related transcription factor 2 (RUNX2),
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and growth differentiation factor 2 or bone morphogenetic protein 9 (BMP-9) was found in HO+
samples (Welch two sample t-test; P< 0.05). These proteins, in combination with potential serum
biomarkers previously reported, are key candidates for a serum diagnostic panel that may enable
early detection of HO prior to radiographic and clinical manifestations.
Introduction
Heterotopic ossification (HO), the abnormal formation of
mature lamellar bone in nonosseous (soft) tissue, is a significant
problem for wounded soldiers that have survived high energy
blast injuries [1,2]. A recent study on soldiers from Operation
Enduring Freedom and Operation Iraqi Freedom reveals that
the highest risk of HO follows amputation from a blast mechan-
ical injury, with HO accounting for >60% combat-related
extremity injuries [1,3]. Of interest, in the military population,
formation of HO is associated with chronic pain, prostheses
not fitting properly, joint ankylosis, functionality limitations,
longer rehabilitation, and substantial morbidity [3]. Addition-
ally, HO occurs post-trauma in elective hip arthroplasty, exter-
nally fixed distal humerus fractures (42%), spinal cord injury
(SCI), and closed brain injury in civilian populations [4].
Treatment regimens for HO are limited by a lack of under-
standing of the cellular events that contribute to disease onset.
Although non-steroidal anti-inflammatory (NSAID) drugs
and radiation therapy used prophylactically can be effective
as a treatment for HO, many patients need at least one surgical
excision of ectopic bone [5]. Multiple diagnoses, including
hemostasis and polytrauma, often present in combat casu-
alties, make these prophylactic treatments contraindicated,
and currently there are no pharmaceutical treatments yet
approved by the United States Federal Drug Administration
to treat HO once present [5].
Recent technological advancements in the field of mass
spectrometry (MS) have enhanced the ability to perform pro-
teomic analysis of biological samples and facilitate the identi-
fication of disease biomarkers [6]. High-throughput MS
techniques, such as isobaric tags for relative and absolute
quantitation (iTRAQ), enable a global analysis of the pro-
teome differences between biological samples. This approach
enables a wholistic data driven experimental design that does
not require a priori specification of protein targets. The objec-
tive of this study was to collect and integrate serum and tissue
proteomes from HO+ and HO subjects, in order to identify
proteins and pathways that are dysregulated in the disease
state and provide insight into potential biomarkers for early
disease detection and monitoring.
Results
Subject demographics and experimental workflow
Forty-four subjects were enrolled in this study. Tissue samples
were collected from 42 subjects with 41 tissue samples having
matched serum samples. HO subjects (n= 33) aged 22–83
years, whereas HO+ subjects (n= 10) aged 22–40 years. The
HO tissue samples were acquired mainly through total hip
arthroplasty, whereas the HO+ samples were acquired via
hip revision or HO excision (Table 1). Serum and tissue sam-
ples were analyzed following the workflow shown in Figure 1.
High-throughput screening and Western blot validation
To identify potential markers for HO, high-throughput anti-
body microarrays were used for an initial screening of 877 cell
signaling proteins by comparing the HO and HO+ groups.
>200 protein candidates had a 50% or greater difference in
spot intensity between the pooled HO and pooled HO+
serum samples. These 200 candidates were further filtered to
remove proteins with high variations for duplicate measure-
ments, flagged protein spots with irregular margins, or proteins
with a global normalized score <800. As a result, 67 targets
were retained for further validation and the top 18 proteins
based on Z-ratios were subjected to Western blotting analysis.
Western blots validated the microarray data for phosphory-
lated GRB2-associated-binding protein 1 (Gab1 Y627) and
apoptosis regulator BAX between the pooled HO+ and pooled
HO samples. However, spot intensity was weak for both
Gab1 Y627 and BAX, and the BAX antibody had strong
non-specific cross reactivity. Weak binding and cross-
reactivity in addition to large sample volume requirements
diminished the utility of Western blotting and as a result no
additional serum samples were analyzed using this technique.
Table 1 Subject demographics
HO HO+
M F Age range (mean) M F Age range (mean)
Subjects
With serum samples 18 13 22–83 (54) 9 1 22–40 (29)
With tissue samples 20 13 22–83 (52) 8 1 22–40 (28)
Injury etiology
Total hip arthroplasty 11 8 28–83 (59)
Open reduction and internal fixation 6 3 25–64 (45)
Hip revision 3 45–62 (56) 1 1 36–40 (38)
HO excision 8 22–31 (26)
Others 3 22–36 (29)
Note: HO, heterotopic ossification; M, male; F, female.
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Using antibody arrays and the filtering criteria described
for serum (above), 54 proteins were selected for Western blot
validation using extracted proteins from pooled HO+ and
pooled HO tissue samples. The levels of phosphorylated
(pS1231) eukaryotic translation initiation factor 4 (eIF4G)
and signal transducer and activator of transcription 1a
(STAT1a) were increased in HO+ tissue samples compared
to HO samples, whereas levels of p38a MAPK and phospho-
rylated (pS37) p53 were down-regulated in HO+ compared to
the HO samples (Figure 2). All other proteins showed compa-
rable expression between HO+ and HO samples. Proteins
with demonstrated differences in abundance between pooled
HO+ and pooled HO tissue samples were further tested on
individual, non-pooled samples; however, the results were
heterogeneous within the HO and HO+ cohorts, highlighting
the complexity and limitations of scaling results from pooled
analyses to the individual level.
Global proteomic survey identified HO-related proteins
iTRAQ was used to generate a semi-quantitative global pro-
teomics survey of serum and tissue from subjects with and
without HO. In total, 1220 and 3770 unique proteins were
assigned UniProtKB Accessions across the biological and
technical replicates of iTRAQ experiments for serum samples
and tissue samples, respectively. Protein abundance obtained
from iTRAQ experiments was expressed as a ratio of protein
levels in HO samples against that in HO+ samples for each
protein quantified. There were 648 proteins that were
quantified in both serum and tissue samples. The ratios for
the majority of proteins identified in serum (85%) and tissue
(92%) were close to 1.0, indicating similar abundances between
HO and HO+ samples.
There were 82 and 281 differentially regulated proteins
(down regulated 0.5; up-regulated 1.5) in serum and tissue,
respectively. Among them, 7 proteins were differentially regu-
lated in both serum and tissue samples. These include osteo-
modulin (OMD), collagen alpha-1(V) chain (COL5A1),
macrophage-capping protein (CAPG), T-lymphoma invasion
and metastasis-inducing protein 1 (TIAM1), C-reactive protein
(CRP), serum amyloid A1 (SAA1), and SAA2. The 281 differ-
entially expressed proteins from tissue samples are part of sev-
eral Reactome pathways, which were significantly enriched
(CLUEGO, P< 0.05). These include degradation of the extra-
cellular matrix, striated muscle contraction, neutrophil degran-
ulation, endosomal/vacuolar pathway, keratin sulfate
degradation, apoptotic cleavage of cellular proteins, interferon
gamma signaling, and latent infection of Homo sapiens with
Mycobacterium tuberculosis (Figure 3A). Several direct pro-
tein–protein interactions (interactome) between the 281 differ-
entially regulated biomarker candidates in tissue samples were
revealed via ReactomeFI analysis (Figure 3B). Four pathways
were enriched within the interactome with a false discovery
rate (FDR) <0.001, including extracellular matrix organiza-
tion, keratinization, neutrophil degranulation, and interferon
gamma signaling. Interestingly, all 12 proteins identified in
the keratinization pathway were down regulated in HO+
compared to HO samples.
Figure 1 Overview of the workflow for HO sample analyses
A hierarchical proteomic analysis was applied to the serum (A) or tissue (B) samples fromHO+ andHO subjects, by combining qualitative
or semi-quantitative antibody arrays andMS shotgun proteomic surveys to detect novel potential biomarkers. Antibody-independent SRM
MS analysis and antibody-dependent ELISA or Western blot quantitative assays were subsequently performed to validate each potential
biomarker. HO, heterotopic ossification; MS, mass spectrometry; SRM, selected reaction monitoring; iTRAQ, isobaric tags for relative and
absolute quantitation.
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Validation of differentially-expressed proteins in individual
samples
Individual HO+ and HO samples were tested using ELISA to
validate potential markers that could be incorporated in a
diagnostic panel for prospective studies. Utilizing the high
throughput proteomic datasets and including proteins previ-
ously associated with HO in the literature, 26 proteins were
analyzed in serum (Figure S1) of which 13 were measured in
tissue as well (Figure S2). Five of the 26 proteins analyzed indi-
vidually in serum samples were significantly different between
HO+ and HO samples (Welch two sample t-test; P< 0.05),
including insulin-like growth factor I (IGF1), osteopontin
(OPN), myeloperoxidase (MPO), runt-related transcription
factor 2 (RUNX2), and growth differentiation factor 2 or bone
morphogenetic protein 9 (BMP-9) (Table 2). All proteins,
except IGF-1, were down-regulated in HO+ compared to
HO serum samples (Table 2). No significant differences were
found for the 13 proteins examined in tissue homogenate, with
interleukin 10 (IL-10) below detectable limits for all tissue sam-
ples. Of interest, BMP-2 showed a down-regulation trend in
HO+ tissue samples relative to their HO samples
(P= 0.060; Figure S2).
Integrative network analysis of differentially expressed proteins
To integrate the data from the tissue and serum analyses, pro-
teins that were differentially regulated between HO+ and HO
cohorts, regardless of the detection methodology, were com-
bined for further analyses of the biological pathways affected
by HO. Proteins identified from serum samples include 5 pro-
teins identified using ELISA, 82 proteins identified using
iTRAQ and 3 proteins using SRM [7]. These 90 serum proteins
were integrated with 281 tissue proteins identified using
iTRAQ and analyzed using ClueGO [8], enabling visualization
of the non-redundant biological terms for the differentially
regulated proteins that can be grouped into networks
(Figure 4). As a result, we identified 15 significantly different
Reactome pathways (P< 0.05). These include biomineral tis-
sue development, skeletal system development, response to
fungus, antimicrobial humoral response, cytokine secretion,
extracellular matrix organization, negative regulation of
defense response, response to interferon-gamma, long-chain
fatty acid import, elastic fiber assembly, supramolecular fiber
organization, protein trimerization, cornification, response to
wounding, and myeloid leukocyte mediated immunity. Among
them, the four pathways biomineral tissue development, skele-
tal system development, extracellular matrix organization, and
response to wounding represent biological processes relevant
to HO disease, which manifests with abnormal bone growth.
Discussion
Identification of biomarkers associated with HO is challenging
because co-morbidities present with disease onset often con-
found analyses [9]. To better elucidate potential biomarker
Figure 2 Western blot analysis to identify biomarkers from tissue samples
Pooled HO (A) or HO+ (B) tissue samples were tested for differential expression of 54 targets selected from semi-quantitative antibody
arrays. Dark outlined arrows indicate the expected positions of the target proteins detected by their respective antibodies, whereas light
outlined arrows indicate the migration positions of target proteins that were not visualized.
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candidates specific to HO formation, a computational work-
flow was developed to integrate data from high-throughput
and targeted proteomic assays of serum and tissue samples
from HO+ and HO subjects. High-throughput, semi-
quantitative, bottom-up, proteomic surveys do not require
pre-determined targets and are therefore useful for discovery
Figure 3 Pathway analysis of the differentially-expressed proteins in tissue samples
The 281 differentially-expressed proteins between HO and HO+ tissue samples from the iTRAQ analysis were used as input for
Cytoscape plugin, ReactomeFI, or ClueGO. A. Pie graph of the distribution for the non-redundant significant gene ontologies (two-sided
hypergeometric test; **P< 0.05). B. Clusters of protein–protein interactions for the differentially-expressed proteins (red and green
indicates downregulation and upregulation in HO+ samples, respectively). Within each cluster multiple pathways are represented because
of the involvement of proteins in many biological processes.
Table 2 Proteins differentially expressed in serum samples between HO+ and HO subject cohorts
Protein name UniProt ID Gene P value
HO+ HO
Mean (pg/ml) Range (pg/ml) Mean (pg/ml) Range (pg/ml)
Runt-related transcription factor 2 Q13950 RUNX2 0.002 1100.1 439.9–2160 2163.1 509.6–6038.5
Insulin-like growth factor I P05019 IGF 0.008 92.5 45–139.8 56.4 3.6–115.6
Growth/differentiation factor 2 Q9UK05 BMP9 0.016 7.9 5.2–11.3 10.4 5.2–24.1
Myeloperoxidase P05164 MPO 0.045 49.5 12.1–127.2 148.7 11.7–1081.4
Osteopontin P10451 OPN 0.039 37.1 5.9–112.9 136.2 0.9–1215.2
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of potential biomarkers. Although quantitative antibody
arrays quickly translate results into biological insight [10],
the protein targets that can be included depend on antibody
availability, sensitivity and specificity. Moreover, most site-
specific post-translational modifications are not quantifiable
using antibodies. To overcome these limitations, high-
throughput MS approaches including iTRAQ and SRM were
used in combination with antibody-based approaches. These
techniques enabled a data driven experimental design and
identified multiple differentially expressed proteins. These
results suggest that HO is caused by the dysregulation of sev-
eral cell signaling pathways and due to complex systemic and
local interactions related to wound healing, as well as the
recruitment of circulating progenitor cells [11].
Of the numerous proteomic analyses and findings for tissue
and serum samples in the present study, five proteins were
identified in individual serum samples as significantly different
between HO+ and HO samples and show promise as poten-
tial clinical biomarkers. These include IGF1, OPN, MPO,
RUNX2, and BMP-9. Expression of each of these proteins,
Figure 4 Integrative network analysis of serum and tissue proteomic data for HO
Proteins that were differentially expressed either in serum (n= 90) or tissue (n= 281) samples between HO+ and HO cohorts, regardless
of detection methodologies, were combined and analyzed collectively with ClueGO, and the significant non-redundant biological GO
terms (P< 0.05) for the differentially-expressed proteins were displayed. The label and nodes of each cluster are colored by the most
significant GO term in the cluster. Nodes showing 2 colors are included in multiple clusters. Node size reflects Kappa score. GO, gene
ontology.
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except IGF-1, was down-regulated in HO+ compared to HO
serum samples and all have a role in bone formation or inflam-
mation. IGF-1 is involved in controlling bone mineralization
and maturation (UniProtKB P05019) and is reported to
enhance BMP-9 induced osteogenic differentiation in mes-
enchymal stem cells [12]. BMP-9 is a circulating inhibitor of
angiogenesis that induces HO in damaged muscle [13] and
can influence bone formation. MPO is a heme protein released
by leukocytes that plays a significant role in inflammation and
oxidative stress at the cellular level [14]. RUNX2 is a transcrip-
tion factor involved in osteoblastic differentiation and skeletal
morphogenesis (UniProtKB Q13950), which has been reported
previously to be aberrantly expressed in HO [15]. OPN is a
potent inhibitor of ectopic calcification and may influence
inflammatory cell function at sites of ectopic calcification by
dissolving minerals [11]. Osteoblasts produce high levels of
OPN, which may connect osteoblasts with the apatite mineral
of bone [16]. For each of these potential biomarkers, addi-
tional functional investigation is required to understand their
specific role in the etiology of HO.
Both similar and contrasting results for protein abundance
for some proteins identified in this workflow have been
reported [12–23]. Contrasting observations may be explained
by the species studied (animal model or human), sample type
(tissue, wound fluid, or serum), the time of sample collection
post-injury, the type of target measured (protein or transcript),
and/or the technique used to measure those targets. Further-
more, the use of tissue samples for biomarker discovery for
HO is complicated by the difficulty identifying disease foci in
sampled tissue, inability to sample repeatedly over time to
monitor disease development and varied tissue types in sam-
ples. These factors are a source of variability for protein
expression, as differences in protein abundance have been
observed even within the same wound bed between the edge
and the center of the wound [24].
In this study, both serum and tissue samples collected from
the same subjects at the same time were analyzed for biomark-
ers of HO. The tissue and serum samples from subjects in this
study represent a wide age range, and age is well known to neg-
atively affect many biological processes including healing [25].
In addition, the sex ratio of HO+ and HO cohorts was not
matched between or balanced within cohort. Sex-dependent
differences in protein expression may be a confounding factor
and source of heterogeneity. Although subjects were tracked
after surgery for the development of HO, the tissue and serum
samples were collected at the time of surgery and all HO+
samples were derived from subjects undergoing HO excision.
Therefore, the samples analyzed in this study reflect serum
and tissue status after HO onset rather than immediately
post-injury as reported previously [13,15,17,21,22]. Typically,
HO excision from tissues occurs 6 months or more after initial
surgery to ensure maturation of the HO tissue, in the hopes of
lowering the risk of recurrence or revision surgery. Under-
standing the dynamics of the transition from high expression
of a protein after an injury to down-regulation over disease
progression could provide insight into potential therapeutic
targets.
Serum is a less-invasive sample compared to tissue and it
can be collected at multiple and pre-determined time points.
On the other hand, collection of tissue requires additional
surgeries for a population already undergoing major surgeries
including amputation and at risk for delayed healing due to
extent of initial injuries. Additional surgeries may slow or pre-
vent prosthetic use or return to functional ability. For these
reasons, serum is more feasible than tissue for tracking HO
onset and more uniform in composition for use in predictive
diagnosis of the disease.
The advantages and disadvantages of shotgun proteomics
compared to high-throughput antibody assays were evident
in this study. Antibody assays are limited by availability of
high quality antibodies (target specificity and limited cross-
reactivity) for necessarily pre-determined protein targets of
interest. The shotgun MS technique iTRAQ was able to over-
come these disadvantages, but results are semi-quantitative.
To further transition iTRAQ findings into a clinical diag-
nostic panel, SRM-MS assays were used to quantitatively
and robustly analyze serum peptides for 3 proteins, osteocal-
cin, osteomodulin, and collagen alpha-1(v) chain isoform 2
[7]; and quantitative antibody assays were used to measure 5
proteins: IGF1, OPN, MPO, RUNX2, and BMP-9, which
are all potential clinical biomarkers for HO. Collectively, these
8 proteins are candidates for a serum diagnostic panel that,
once validated, may detect onset of HO.
In conclusion, our results support that a multi-protein lon-
gitudinal assay is required for an effective biomarker panel for
HO. Linking these biomarkers to potential new therapies is
essential for improving patient outcomes. Our data support
that multiple cell signaling pathways in both serum [7] and tis-
sue, including extracellular matrix organization and kera-
tinization, are dysregulated in subjects that develop HO and
are potential cellular processes to target. Ultimately, as preci-
sion medicine efforts continue to drive the use of advanced
technologies, including LC-MS/MS and next generation
sequencing, a multi-protein panel approach, coupled to
advanced analytics, is a clinically relevant and viable diagnos-
tic platform for detection and monitoring of HO.
Materials and methods
Subject enrollment
Subjects under treatment for high-risk fractures, acetabular
fractures, burns with orthopedic injury, traumatic brain injury
with extremity trauma, amputation, excision of ectopic bone,
or major arthroplasty were enrolled into this study. Subjects
aged 18 years or subjects being treated for cancers or meta-
static disease involving bone were excluded. All subjects were
enrolled prior to surgery. Surgical procedures included total
hip arthroplasty, open reduction and internal fixation, hip revi-
sion, incision and drainage below knee amputation, intrame-
dullary nailing, and HO excision. The HO tissue samples
were acquired mainly through total hip arthroplasty, whereas
the HO+ samples were acquired via hip revision or HO exci-
sion. Disease state, HO+ or HO, was determined by evalua-
tion of radiographs that were collected at time of surgery, and
follow-up visits at 6 weeks, 12 weeks, 6 months, and 12
months. Written informed consent was obtained from all
subjects.
Sample collection and processing
Blood (5cc) and tissue samples were collected, at a single time
point, during the surgical procedure at the same time. Serum
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was processed and snap frozen in liquid nitrogen and stored at
80 C prior to use as previously reported [7]. Tissue removed
at surgery was placed in a sterile 50-ml conical tube and stored
at 80 C until protein extraction.
Frozen tissue was thawed on ice and 1 g (wet weight) was
collected into a sterile petri dish and minced with scalpel blade.
Tissue was homogenized in 15 ml ice-chilled lysis buffer
(http://www.kinexus.ca/ourServices/microarrays/antibody_
microarrays/details/index.html; Kinexus, Vancouver, BC,
Canada) containing EDTA-free 1 mM dithiothreitol (DTT)
and 1 protease inhibitor inhibitors (HALTTM, ThermoFisher
Scientific, Waltham, MA) in a T10 115 V Disperser (coupled
with an S10N-10G stainless steel dispersing element) with 3–
5 repeated 15-sec pulses and sonicated (Ultrasonic Processor,
Model GEX130, IKA-Works, Inc., Wilmington, NC) (130
W) with 4 repeated 10-sec pulses at 50% amplitude. Samples
were centrifuged (Hettich MIKRO 220R, Andreas Hettich
GmbH & Co.KG (Hettich), Tuttlingen, Germany) first at
6000  rcf g for 10 min  2 at 4 C to pellet tissue debris and
then at 14,000  rcf g for 30 min at 4 C. Protein concentra-
tion of the resulting supernatant was determined in duplicate
using the Bradford method (Catalog No. 500-0006, BioRad,
Hercules, CA) in microplate format with bovine IgG (Catalog
No. 500-0005, BioRad) as the standard. Supernatants were ali-
quoted into 1.5-ml Protein LoBind Eppendorf tubes (Eppen-
dorf 02243108, Hamburg, Germany) and stored at 80 C.
Antibody microarray
HO and HO+ samples, from 4 subjects, were pooled sepa-
rately and screened using an 877 target antibody microarray
according to the manufacturer’s specifications (catalog No.
KAM-850, Kinexus). Candidate biomarkers were selected con-
sidering: (1) the degree of change observed between HO and
HO+ pools with ±50% clash free crossovers (CFC); (2) the
intensity of the globally normalized signal intensity score
>800; (3) the sum of the % error range in the duplicate mea-
surements for each HO and HO+ antibody pair and their
comparison to the % CFC value (set as sum <80% of CFC
value); and (4) ranked Z-ratio scores.
Mass spectrometry
Equal amounts of protein from each subject were pooled
according to the disease status. Thirty-one HO and 10
HO+ serum samples, as well as 33 HO and 9 HO+ tissue
samples were included for mass spectrometry analysis as previ-
ously reported [7]. The average labeling efficiency of all
iTRAQ quantitative channels (MyOmicsDx, Towson, MD)
was 99.2% through Proteome Discoverer (version 2.2) with a
repetitive random sampling of 1000 peptides from the entire
quantified peptidome.
Quantitative antibody assay
Protein abundance in serum and tissue homogenates was mea-
sured in duplicate by commercial assay services (Assaygate,
Ijamsville, MD) using bead-based multiplex suspension arrays
with the Bio-Plex 200 Bead Reader System or conventional
solid phase sandwich enzyme linked immunoassay (ELISA).
Thirteen targets were measured in both serum and tissue
homogenates, procalcitonin, matrix metalloproteinase-9
(MMP-9), stromal cell-derived factor 1 (SDF-1a), transform-
ing growth factor beta-2 (TGFb2), bone morphogenetic pro-
tein 2 (BMP-2), BMP-9, BMP-4, interleukin-6 (IL-6), tumor
necrosis factor alpha (TNF-a), macrophage inflammatory pro-
tein 1-alpha (MIP-1a), monocyte chemoattractant protein-1
(MCP-1), IL-10, and C-X-C motif chemokine 10 (CXCL10).
An additional 13 targets were measured in serum samples only,
cartilage oligomeric matrix protein (COMP), IGF1,
thrombospondin-1 (THBS1), pro-epidermal growth factor
(EGF), OPN, MPO, secreted protein acidic and rich in cys-
teine (SPARC), TGFb1, RUNX2, talin-1 (TLN1), plasmino-
gen, fibroblast growth factor receptor 1 (FGFR1), and
gremlin-1. Differences in protein concentration between
HO+ and HO samples were tested using Welch two-sample
t-test with significance for P< 0.05.
Pathway and gene ontology analysis
Bioinformatics analyses of iTRAQ data were performed
using Cytoscape v3.3.0 [26] and the ReactomeFI plugin
(database 2016) [27]. Gene ontology enrichment analysis
was performed using the Cytoscape applications BiNGO
[28], REVIGO [29], and ClueGO [8]. BiNGO parameters
were as following: over presentation of gene ontologies after
FDR correction, hypergeometric test, Benjamini–Hochberg
FDR correction, P< 0.05, and GO: biological processes.
BiNGO results were up-loaded into REVIGO and analyzed
using default settings. ClueGO parameters were as following:
ClueGO functions, Reactome pathways, P< 0.05, enrich-
ment/depletion (two-sided hypergeometric test), and prefuse
force directed layout.
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